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Long-term Efficacy and Safety of Atorvastatin in
Dyslipidemic Patients Undergoing Continuous
Ambulatory Peritoneal Dialysis
Elias V. Balaskas, Athanasios Sioulis, Eva Patrikalou, Haralampos Kampouris, Achilleas Tourkantonis
Objective: Lipid abnormalities are common in patients on continuous ambulatory peritoneal dialysis (CAPD)
and they are risk factors for atherosclerosis. In this prospective uncontrolled study, the aim was to evaluate the
efficacy and safety of atorvastatin, a new statin, in hypercholesterolemic CAPD patients with or without
hypertriglyceridemia who failed to respond to diet control.
Methods: Following a hypolipidemic diet for 2 months, atorvastatin was administered at a dose of 10 mg/day
once daily in 24 patients (14 males, 10 females). Mean age was 59.9 years (range, 19–74 years) and average
time on CAPD was 16.6 months (range, 4–52 months). The results were evaluated at 0, 1, 3, 6, 12, 18, 24, 30,
36, 42, and 48 months. A total of three patients received atorvastatin for longer than 48 months, eight patients
received it for longer than 42 months, 10 patients for longer than 36 months, 17 patients for longer than 24
months, 20 patients for longer than 18 months, and all (24) patients for longer than 12 months.
Results: Highly significant decreases were noted in total cholesterol (from 282 ( 28 to 178 ( 22 mg/dL,
20–50%, mean, 34%; p < 0.001), low-density lipoprotein cholesterol (from 198 ( 25 to 112 ( 20 mg/dL,
21–53%, mean, 37%; p < 0.001), and triglycerides (from 256 ( 116 to 177 ( 40 mg/dL, 12–45%, mean, 28%,
p < 0.01) from the sixth month. High-density lipoprotein cholesterol was significantly increased from the sixth
month (from 40 ( 9 to 48 ( 9 mg/dL, 11–28%, mean, 19.4%; p < 0.01). These changes remained steady during
the study. No liver function abnormalities were observed and serum creatinine kinase levels remained within
normal limits during treatment. No complications or other side effects were detected.
Conclusions: Our data indicate that atorvastatin, even at a low dose of 10 mg/day, is an effective, safe, and
well-tolerated drug for the long-term treatment of hyperlipidemia in CAPD patients. [Hong Kong J Nephrol
2003;5(2):78–83]
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INTRODUCTION
The most common cause of death in patients with end-
stage renal disease (ESRD) on maintenance dialysis is
cardiovascular disease [1]. Lipid abnormalities are
major risk factors for cardiovascular disease and are
frequently observed among patients with ESRD,
especially those on dialysis [2]. The dyslipidemia of
ESRD is characterized by hypertriglyceridemia,
reduced high-density lipoprotein cholesterol (HDL-C),
and elevated low-density lipoprotein cholesterol (LDL-
C), with a marked predominance of highly atherogenic,
small and dense LDL particles [3–5]. In various studies,
30% to 70% of dialysis patients exhibit hyper-
triglyceridemia [3]. Moreover, peritoneal dialysis (PD)
patients are at greater risk of developing hyper-
cholesterolemia, primarily because of lipoprotein
overproduction resulting from both the absorption of
dialysate glucose and the loss of proteins into the
peritoneal effluent [6–9]. These patients’ lipid profiles
are also characterized by increased plasma
apolipoprotein B (Apo-B) and lipoprotein (a) (Lp(a))
levels, and according to a meta-analysis, 24% of PD
patients have total cholesterol (TC) levels that are
greater than 240 mg/dL, and 45% have plasma LDL-C
levels that are greater than 130 mg/dL [8–11].
The combination of dyslipidemia and other
coexistent risk factors such as hypertension, diabetes,
and obesity is likely to contribute to the marked increase
in the risk of cardiovascular morbidity and mortality
in patients undergoing dialysis relative to the general
population [12–14].  This is  true for hyper-
cholesterolemia and also hypertriglyceridemia, which
acts synergistically with decreased HDL-C [15],
although some studies suggest that hypertri-
glyceridemia might even be an independent coronary
risk factor [16,17].
In order to improve the prevention of cardiovascular
disease in clinical practice, many recommendations
have been produced, based on data from clinical,
epidemiologic and observational studies [18,19].
Central to such recommendations is TC level reduction,
in particular the lowering of LDL-C. The higher than
average incidence of potential cardiovascular
complications as the leading cause of death in PD
patients argues strongly in favor of treating lipid
disturbances. Caution is no longer acceptable, as in the
past, when the safety of effective hypolipidemic agents
in these patients remained questionable [20]. Despite
the effect of lipid-lowering dietary recommendations
on nutritional intake and lipid profiles, the vast majority
of dyslipidemic dialysis patients require pharmacologic
therapy to improve their lipid profiles [21].
The introduction of the well-tolerated and safe
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitors, or statins, despite limited evidence
of their effectiveness in dialysis patients, has made them
the most widely used class of drug in the treatment of
hyperlipidemia complicating chronic renal disease,
including in hemodialysis and PD patients [8,22–26].
Atorvastatin, an established member of the statins drug
class, lowers both cholesterol and triglyceride (TG)
levels [27–34]. It has been shown to provide statistically
significantly greater reductions in LDL-C and TC than
milligram-equivalent doses of simvastatin, pravastatin,
lovastatin, and fluvastatin [27]. Atorvastatin, at its
maximum dose of 80 mg/day, reduces LDL-C levels
by up to 61% and TG levels by up to 45% [28], with no
serious compromise to its safety profile [29]. As
reported in recent studies, atorvastatin was effective
and safe in dyslipidemic PD patients after a period of 4
months’ administration [35,36].
In this prospective uncontrolled study, we assessed
the long-term efficacy and safety of atorvastatin in
dyslipidemic patients with chronic renal failure
undergoing continuous ambulatory peritoneal dialysis
(CAPD) and receiving a single daily dose of 10 mg.
PATIENTS AND METHODS
This prospective uncontrolled study took place from
March 1998 to June 2002, and included 24 patients and
was planned to have a follow-up duration of at least 12
months for all patients. Atorvastatin was already a drug
in use and patients knew that it was a lipid-lowering
drug. The study was approved by our hospital’s Ethics
Committee and all the patients gave informed consent.
All patients who had been on PD for more than 3
months in our unit were considered for entry into the
study if they were 18 years of age or older. To be eligible
for inclusion, patients at screening were required to have
dyslipidemia documented by at least two plasma
determinations (TC * 200 mg/dL and LDL-C *
135 mg/dL with or without hypertriglyceridemia), and
no hypolipidemic treatment in the previous 3 months
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or dyslipidemia uncontrolled by treatment with
maximally tolerated doses of other lipid-lowering
agents taken for a minimum period of 4 weeks.
Exclusion criteria included age of less than 18 years
or greater than 80 years, history of hypersensitivity to
HMG-CoA reductase inhibitors, hypothyroidism,
severe progressing disease, cachexia, women who were
pregnant or breastfeeding, active liver disease or hepatic
dysfunction defined as plasma transaminases (alanine
transaminase and aspartate transaminase) greater than
three times the upper limit of normal, creatinine kinase
greater than three times the upper limit of normal,
history of alcohol abuse, concurrent treatment with
long-term immunosuppressants, medication affecting
lipoprotein metabolism, drugs associated with
rhabdomyolysis in combination with statins (such as
cyclosporine, erythromycin, azole antifungals), and
fibrate therapy. Patients with myocardial infarction,
transient ischemic attack, percutaneous transluminal
coronary angioplasty or coronary artery bypass graft
within 3 months of study entry were also excluded, as
were those with unstable diabetes mellitus, participation
in another clinical trial within 1 month prior to study
entry, and clinical evidence of inflammatory muscle
disease.
TC, HDL-C, LDL-C, and TG levels were measured
before initiating the study treatment. The same
parameters were measured monthly during the study.
Following a hypolipidemic diet for 2 months, all the
patients received a single daily dose of atorvastatin
10 mg at bedtime. This dose remained unchanged
during the first 3 months of the study, after which it
could be increased to 20 mg if the target LDL-C level of
130 mg/dL or less and the target TG level of
200 mg/dL or less for all patients were not achieved.
Safety was assessed by clinical and laboratory
monitoring before treatment, then once per month until
the end of the study (liver and muscle enzyme level
determinations: alanine aminotransferase [ALT],
aspar ta te  aminotransferase  [AST],  gamma-
glutamyltransferase [GGT], creatine phosphokinase,
and aldolase).
Student’s t test for paired variables and Wilcoxon’s
non-parametric test were used to compare the
differences between lipid parameters at baseline and
on treatment (repeated measures). Results are expressed
as mean ( standard deviation and as mean percentage
decrease.
RESULTS
A total of 24 patients were eligible for inclusion and
were finally included: 14 males and 10 females. Mean
age was 59.9 ( 20 years (range, 19–74 yr), and the mean
duration of CAPD treatment was 16.6 ( 13.4 months
(range, 4–52 mo). The primary renal diseases were:
diabetes mellitus (nine patients, two of whom had type
I ) ,  h y p e r t e n s i o n  ( f ive  p a t i e n t s ) ,  c h r o n i c
glomerulonephritis (four patients), polycystic kidney
disease (two patients), chronic pyelonephritis (two
patients), and unknown cause (two patients). Lipid
parameters were measured every month, at the monthly
visit of the patients, and the results were evaluated at
the start (baseline) and then at 1, 3, 6, 12, 18, 24, 30,
36, 42, and 48 months. From the third month, the
reported lipid levels were the average of three
consecutive measurements.
A total of three patients received atorvastatin for
more than 48 months, eight patients for more than 42
months, 10 patients for more than 36 months, 17
patients for more than 24 months, 20 patients for more
than 18 months, and all (24) patients for more than 12
months. Atorvastatin was administered at a dose of
10 mg, once daily, at bedtime, and only in five patients
was the dose increased to 20 mg/day because the target
level (130 mg/dL) of LDL-C was not achieved at the
end of the third month of treatment.
A significant decrease with respect to baseline was
observed for TC and LDL-C after 1 month of treatment
with atorvastatin 10 mg daily, whereas no significant
change was observed in TG and HDL-C levels. At the
end of the sixth month of treatment, and after the
atorvastatin dose was increased to 20 mg/day in five
patients, there was also a significant decrease in TG
levels and a significant increase in HDL-C levels
(Table 1).
At the end of the study, there were more significant
changes from baseline for all the lipid parameters, as
shown in the Figure. The results showed the following:
highly significant decreases in TC of 20% to 50%
(mean, 34%; p < 0.001), in LDL-C of 21% to 53%
(mean, 37%; p < 0.001), in TG of 12% to 45% (mean,
28%; p < 0.01), and increase in HDL-C of 11% to 28%
(mean, 19.4%; p < 0.01). These changes remained
almost steady during the study, as shown in Table 2.
Six patients achieved LDL-C levels of less than
100 mg/dL, and the vast majority of the patients had
Table 1. Change in lipid parameters after 6 months of atorvastatin
10 mg (n = 19) or 20 mg (n = 5) after the third month.
Day 0 Month 6 Change (%)
TC 282 ( 28 190 ( 30 –32*
LDL-C 198 ( 25 120 ( 29 –39*
TG   256 ( 116 189 ( 61 –26†
HDL-C 40 ( 9   46 ( 11 +15†
*p < 0.001, †p < 0.01, with respect to baseline values. Values are
mean ( SD (mg/dL). TC = total cholesterol; LDL-C = low-density
lipoprotein cholesterol; TG = triglycerides; HDL-C = high-density
lipoprotein cholesterol.
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LDL-C values between 100 mg/dL and 130 mg/dL.
There was no change in the uremic profiles of the
patients, nor were there any alterations in medications
(antihypertensives, hypoglycemic control), diet,
exercise, or CAPD schedule that might have affected
lipid profiles during the study. Complete clinical and
laboratory evaluations were performed every month.
There were no cardiovascular events during the study,
no withdrawals from the study, and all the patients
remained on CAPD at the end of the study.
No liver function abnormalities were observed and
all liver and muscle enzyme levels (ALT, AST, GGT,
creatine phosphokinase, and aldolase) remained within
normal limits during the study. No complications, side
effects or adverse events were detected.
DISCUSSION
The need to treat lipid abnormalities complicating renal
disease is unproven. However, it seems likely that the
high prevalence of dyslipidemia in dialysis patients
contributes to the elevated risk of cardiovascular
morbidity and mortality in this patient population [36].
In guidelines for the prevention of coronary heart
disease in clinical practice, renal dysfunction is
classified together with existing coronary heart disease
and type 2 diabetes as diseases that confer a high risk
of future coronary events and for which lipid-lowering
therapy is recommended for all patients [18]. However,
as reported by Harris et al [36], only 16% of dialysis
patients were receiving treatment with lipid-lowering
drugs, and of those patients on therapy, only 50% had
achieved an LDL-C of less than 115 mg/dL. These data
suggest that more aggressive treatment of dyslipidemia
may be indicated in this patient population.
The reduction in LDL-C and the overall efficacy of
atorvastatin observed in our study was similar to that
reported in two previous studies in uremic patients on
PD [35,36] and in non-uremic patients using the drug
[27–34]. In this last group of patients, it was as expected
because renal dysfunction has been shown not to alter
the pharmacokinetics or LDL-C reduction of
atorvastatin [37]. Our study confirms previously
reported observations that atorvastatin reduces LDL-C
levels significantly more than other statins [22,23,
26–29,35,36].
In primary hypertriglyceridemia, the reduction in
TG levels achieved with atorvastatin is dose-dependent
and greater than with other statins: 26% to 46% for
daily doses ranging from 5 mg to 80 mg [30]. A similar
reduction was observed in our study; the 12% to 45%
reduction in TG with the lowest atorvastatin dose of
10 mg confirms the results of previous studies with
atorvastatin in PD patients [35,36], and the reduction
is greater than that obtained with other statins in the
same patient population, in which TG reduction ranged
from 6.2% to 22% [22,23,26].
In our study, there was a significant increase in
HDL-C levels after the sixth month of treatment; this
observation is in agreement with one previous study
[36], but not with another [35]. The ability of
atorvastatin to modify TG and HDL-C levels
beneficial ly is  important  because abnormal
concentrations of these lipids characterize the usual
Table 2. Lipid parameters during the study.
Day 0 Month 6 Month 12 Month 18 Month 24 Month 36
(n = 24) (n = 24) (n = 24) (n = 20) (n = 17) (n = 10)
TC 282 ( 28 190 ( 30* 185 ( 26* 187 ( 24* 180 ( 25* 178 ( 22*
LDL-C 198 ( 25 120 ( 29* 115 ( 20* 113 ( 21* 116 ( 18* 112 ( 20*
TG   256 ( 116 189 ( 61† 190 ( 40† 185 ( 45† 182 ( 38† 177 ( 40†
HDL-C 40 ( 9   46 ( 11* 45 ( 9†   48 ( 12*   49 ( 10*  48 ( 9†
*p < 0.001, †p < 0.01, with respect to baseline values. Values are mean ( SD (mg/dL). TC = total cholesterol; LDL-C = low-density
lipoprotein cholesterol; TG = triglycerides; HDL-C = high-density lipoprotein cholesterol.
Figure. Summary of percent change from baseline for lipid
parameters at the end of the study. *p < 0.001, †p < 0.01. TC = total
cholesterol; LDL-C = low-density lipoprotein cholesterol;
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pattern of dyslipidemia observed in uremic patients and
may also contribute to the elevated cardiovascular risk
seen in dialysis patients [8].
Atorvastatin was well tolerated in our study. With
the lowest dose of 10 mg but the long duration of
treatment, there were no liver function abnormalities,
muscle enzyme level elevations, cardiovascular events,
complications or other side effects. All the studies with
atorvastatin have reported that it is well tolerated and
better tolerated than other statins, both in subjects with
normal renal function and in uremic patients [27–36].
Atorvastatin is effective and safe in reducing the
dyslipidemic components (LDL-C and TG) that are
observed in uremic patients on PD. Despite these
results, there remains a pressing need for large,
prospective, randomized, controlled trials with long-
term follow-up to determine the effects of lipid-
lowering therapy on cardiovascular morbidity and
mortality in dialysis and pre-dialysis patients [36].
It seems that statins (their effects on plasma lipid
levels notwithstanding) have ancillary actions that may
be relevant to nephrology [38]. It is reported that statins
may have important effects on the pathophysiology of
progressive renal injury, including effects on
inflammatory processes, cell proliferation, and
intracellular signaling pathways [39,40]. Furthermore,
as recent studies have shown, statins may have effects
on hemostatic parameters such as platelet aggregation,
endothelial function, and fibrinolysis in CAPD patients
[41–43]. Therefore, future studies are warranted to
investigate the potential role of lipid-lowering therapy
in chronic renal disease and in patients on PD.
In conclusion, our data indicate that atorvastatin,
even at the lowest dose of 10 mg/day, is an effective,
safe, and well-tolerated lipid-lowering drug for the
long-term treatment of dyslipidemia in PD patients.
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